September 20, 2011
Takeda Pharmaceutical announced on September 16 that it has initiated a domestic PIII clinical trial for TAK-438, a treatment for acid-related diseases, which the company is developing exclusively in Japan. Takeda positions TAK-438 as a successor to the proton pump...read more